Alkermes Moves Beyond Reformulations As It Preps Three New Compounds For Clinic
This article was originally published in Pharmaceutical Approvals Monthly
Alkermes multi-year efforts to move up from its successful reformulations for partners takes a step forward as the biotech presents its expanding clinical pipeline to investors, highlighting early-stage compounds for multiple sclerosis, pain and cancer.
You may also be interested in...
Biogen Idec’s Tecfidera Goes To Market With Claim For Delay Of Disability Progression
FDA approved the oral multiple sclerosis drug March 27 to treat patients with relapsing forms of the disease. Labeling includes data from one trial that showed patients on Tecfidera experienced disability progression less often.
Long-Acting Atypical Antipsychotic Market Snapshot: A One-Company Market Begins To Diversify
Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.